Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Hepatic Encephalopathy Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Hepatic Encephalopathy Overview | 8 | 1 |
| Hepatic Encephalopathy Therapeutics under Development by Companies | 9 | 1 |
| Hepatic Encephalopathy Pipeline Products Glance | 10 | 4 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Unknown Stage Products | 13 | 1 |
| Hepatic Encephalopathy Products under Development by Companies | 14 | 1 |
| Hepatic Encephalopathy Companies Involved in Therapeutics Development | 15 | 8 |
| Alfa Wassermann S.p.A | 15 | 1 |
| Cosmo Pharmaceuticals S.p.A | 16 | 1 |
| Horizon Pharma Plc | 17 | 1 |
| KannaLife Sciences, Inc. | 18 | 1 |
| Ocera Therapeutics, Inc. | 19 | 1 |
| Rebiotix Inc. | 20 | 1 |
| Spherium Biomed S.L. | 21 | 1 |
| Umecrine Cognition AB | 22 | 1 |
| Hepatic Encephalopathy Therapeutics Assessment | 23 | 9 |
| Assessment by Monotherapy Products | 23 | 1 |
| Assessment by Target | 24 | 2 |
| Assessment by Mechanism of Action | 26 | 2 |
| Assessment by Route of Administration | 28 | 2 |
| Assessment by Molecule Type | 30 | 2 |
| Drug Profiles | 32 | 20 |
| glycerol phenylbutyrate Drug Profile | 32 | 5 |
| GR-3027 Drug Profile | 37 | 1 |
| KLS-13019 Drug Profile | 38 | 1 |
| ornithine phenylacetate Drug Profile | 39 | 5 |
| RBX-2477 Drug Profile | 44 | 1 |
| rifamycin CR Drug Profile | 45 | 2 |
| rifaximin Drug Profile | 47 | 4 |
| THDP-17 Drug Profile | 51 | 1 |
| Hepatic Encephalopathy Dormant Projects | 52 | 1 |
| Hepatic Encephalopathy Product Development Milestones | 53 | 10 |
| Featured News &Press Releases | 53 | 1 |
| Apr 15, 2016: Ocera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL) | 53 | 1 |
| Apr 11, 2016: Ocera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of Hepatology | 54 | 1 |
| Jan 08, 2016: Ocera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy | 54 | 1 |
| Dec 09, 2015: Umecrine Cognition Announces Grant Of a US Patent Protecting Its Lead Candidate Drug GR3027 | 55 | 1 |
| Nov 16, 2015: Ocera Announces Positive Phase 1 Results for Oral OCR-002 in Development for the Prevention of Chronic Hepatic Encephalopathy | 56 | 1 |
| Sep 16, 2015: Ocera Initiates Phase 1 Clinical Trial of Oral Drug Candidate OCR-002 for Prevention of Hepatic Encephalopathy | 57 | 1 |
| Aug 19, 2015: Umecrine Cognition announces the publication of preclinical results of the candidate drug GR3027 aimed for the treatment of hepatic encephalopathy | 58 | 1 |
| Aug 11, 2015: Kannalife Sciences Discusses Orphan Drug Opportunity for KLS-13019 | 58 | 1 |
| Apr 20, 2015: Lupin Launches Zaxine in Canada | 59 | 1 |
| Apr 01, 2015: Ocera Completes Interim Analysis of OCR-002 in Phase 2b STOP-HE Study for the Treatment of Acute Hepatic Encephalopathy | 59 | 1 |
| Sep 18, 2014: Salix Secures Additional Intellectual Property Relating to Rifaximin | 60 | 1 |
| Sep 12, 2014: Lupin and Salix Announce Exclusive Distribution Agreement for Zaxine in Canada | 60 | 1 |
| Feb 25, 2014: Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate for the Treatment of Hepatic Encephalopathy in Hepatology | 61 | 1 |
| Feb 14, 2014: Luxembourg National Health Fund Approves Reimbursement Of Xifaxan 550 | 61 | 1 |
| Feb 04, 2014: Salix Pharmaceuticals Announces Issuance Of U. S. Patent For Rifaximin | 62 | 1 |
| Appendix | 63 | 2 |
| Methodology | 63 | 1 |
| Coverage | 63 | 1 |
| Secondary Research | 63 | 1 |
| Primary Research | 63 | 1 |
| Expert Panel Validation | 63 | 1 |
| Contact Us | 63 | 1 |
| Disclaimer | 64 | 1 |